← feed

Is NCT02639091 results overdue?

Yes — results are overdue. Primary completion was 2018-05-23; the FDAAA-801 reporting deadline (2019-05-23) passed 2632 days ago and no results are posted on ClinicalTrials.gov.

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

NCT IDNCT02639091 ↗
SponsorBayer (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2018-05-23 (ACTUAL)
Reporting deadline2019-05-23 (completion + 365d)
Days overdue2632
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 5e27577d2b715173… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02639091. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →